Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
86%
Prostate Cancer
67%
Abiraterone Acetate
44%
Castration-resistant Prostate Cancer
41%
Prednisone
34%
Prostate-specific Antigen
30%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
29%
Prostate Cancer Patients
27%
Androgen Receptor
26%
Docetaxel
26%
Androgen Deprivation Therapy
26%
Advanced Prostate Cancer
25%
Overall Survival
24%
Chemotherapy
24%
Abiraterone
21%
Androgens
19%
Phase II Study
16%
Cancer Clinical Trials
14%
Hormone-sensitive Prostate Cancer
14%
Nave
13%
Androgen Receptor Antagonist
12%
Clinical Trials
12%
Patient Management
11%
Consensus Conference
10%
Disease Progression
10%
Testosterone
10%
Clinical Outcomes
10%
Confidence Interval
10%
Hazard Ratio
9%
Enzalutamide
9%
Phase II Trial
9%
Patients with Prostate Cancer
8%
Adrenal Androgens
8%
Antiandrogen
8%
Tumor
8%
Adverse Events
7%
Androgen Signaling
7%
Castration-resistant
7%
Ketoconazole
7%
BRCA2
7%
Radiographic Progression-free Survival
7%
Prostate Radiotherapy
7%
Phase I Study
6%
Recurrent Prostate Cancer
6%
Insulin-like
6%
Hormonal Therapy
6%
Bone Metastasis
6%
Secondary Hormonal Therapy
6%
Twice Daily
6%
Antitumor Activity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
99%
Prostate Cancer
93%
Androgen
47%
Abiraterone Acetate
43%
Prostate Specific Antigen
35%
Prednisone
34%
Chemotherapy
32%
Docetaxel
28%
Androgen Receptor
26%
Overall Survival
25%
Diseases
21%
Abiraterone
19%
Clinical Trial
18%
Neoplasm
14%
Progression Free Survival
12%
Malignant Neoplasm
10%
Disease Exacerbation
9%
Adverse Event
8%
Hormone Cancer Therapy
7%
Enzalutamide
7%
Ketoconazole
6%
Phase II Trials
6%
Biological Marker
6%
Bone Metastasis
6%
Placebo
6%
Antiandrogen
5%
Antitumor Activity
5%
Solid Malignant Neoplasm
5%
Medicine and Dentistry
Prostate Cancer
100%
Castration Resistant Prostate Cancer
40%
Androgen
26%
Androgen Receptor
19%
Diseases
17%
Prostate Specific Antigen
15%
Clinical Trial
15%
Androgen Deprivation Therapy
14%
Neoplasm
12%
Overall Survival
11%
Hormone Therapy
11%
Metastatic Carcinoma
10%
Malignant Neoplasm
9%
Abiraterone Acetate
7%
Docetaxel
7%
Antiandrogen
7%
Disease Exacerbation
6%
DNA Repair
5%
BRCA2
5%
Immunotherapy
5%
Prostate Specific Membrane Antigen
5%
Germ Cell
5%
Solid Malignant Neoplasm
5%